X-Therma is a biotechnology firm specializing in developing advanced biopreservation solutions for regenerative medicine and organ transplantation. Founded in 2014, the company is headquartered in Richmond, California. X-Therma has raised significant funding to support its innovative projects, including a notable $22.4 million in a Series B funding round completed in early 2024. The founders of X-Therma are Xiaoxi Wei, Ph.D., and Mark Kline, who have pioneered the development of a unique biomimetic biopreservation technology that mimics natural antifreeze molecules found in Arctic organisms.
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | Richmond, California |
| Founders | Xiaoxi Wei, Ph.D., Mark Kline |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Undisclosed investors in Series B funding |
| Industry | Biotechnology |
| Number of Employees | Approximately 100 employees |
X-Therma was founded in 2014 by Xiaoxi Wei, Ph.D., and Mark Kline. The company emerged from research focusing on antifreeze proteins found in Arctic species. These proteins inspired X-Therma's development of biomimetic molecules, referred to as peptoids, designed to prevent ice formation at low temperatures—a significant issue in cell and tissue preservation. Initial funding enabled the company to advance its biotechnological research and develop key products like XT-Thrive®, aimed at addressing unmet needs in organ preservation and transportation.
X-Therma's core technology is centered around its biomimetic peptoids, which provide a novel approach to biopreservation, offering chemical stability and biocompatibility. These peptoids serve to inhibit ice formation, allowing for prolonged storage of biological materials under sub-zero temperatures without compromising their integrity.
X-Therma aims to revolutionize organ transplantation by extending the preservation time window, enhancing transportation logistics, and increasing the availability of viable organs for transplant. Its technologies are set to play a crucial role in the development of regenerative medicine therapies.
Currently, X-Therma is focused on finalizing its flagship products' development to facilitate widespread clinical and commercial application. The company's unique position in the biopreservation space provides it a competitive edge, especially in the burgeoning market of regenerative medicine and cell therapy.
The successful integration of its biopreservation technology into existing clinical protocols showcases a significant potential for decreasing global organ shortages, improving organ transportation regimens, and enabling advancements in tissue engineering.
X-Therma stands as a pioneering entity within the biotechnology industry, particularly in the fields of regenerative medicine and organ preservation. The company's innovative approach employs biomimetic molecules to overcome time constraints in biological preservation, offering promising solutions for critical health challenges. With recent financial backing and FDA regulatory milestones, X-Therma is poised to expand its influence in the biotechnology space, with a vision for transforming healthcare delivery in organ transplantation and regenerative therapies. Looking ahead, X-Therma's dedication to innovation and capability to resolve complex preservation issues will likely facilitate broader contributions to healthcare globally.